FY27 revenue growth: low-to-mid teens
Management expects revenue growth in the low-to-mid teen percentage range for FY27, assuming stable macro conditions.
EMCUREPHARMACEUTICALS / guidance tracker
Keep management guidance in view.
Emcure Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA margin expansion: 75-100 bps
Management committed to expanding EBITDA margins by 75-100 basis points in FY27, driven by operating leverage and productivity gains.
Capex guidance: ₹400-425 crore for FY27
Capital expenditure for FY27 is expected to be in the range of ₹400-425 crore.
Semaglutide (Pista) steady growth in FY27
Aim for steady growth of the semaglutide brand Pista in FY27, leveraging competitive pricing and clinical differentiation.